Malignancies after heart transplantation: Incidence, risk factors, and effects of calcineurin inhibitor withdrawal

Transplantation Proceedings

Volumn 42, Issue 9, 2010, Pages 3694-3699

  Doesch, A O ^a   Mller, S ^a   Konstandin, M ^a   Celik, S ^a   Kristen, A ^a   Frankenstein, L ^a   Ehlermann, P ^a   Sack, F U ^a   Katus, H A ^a   Dengler, T J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CARDIAC GRAFT REJECTION; CARDIOMYOPATHY; CD4+ T LYMPHOCYTE; CLINICAL EVALUATION; CLINICAL PROTOCOL; CONGENITAL HEART DISEASE; CORONARY ARTERY DISEASE; DEATH; DISEASE ASSOCIATION; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART GRAFT; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; LEUKEMIA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MYELOMA; ORGAN DONOR; OVERALL SURVIVAL; PATIENT MONITORING; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRECANCER; PRIORITY JOURNAL; RESTRICTIVE CARDIOMYOPATHY; RISK FACTOR; SQUAMOUS CELL CARCINOMA; THERAPY EFFECT; TREATMENT DURATION; TREATMENT WITHDRAWAL; VALVULAR HEART DISEASE;

ADOLESCENT; ADULT; AZATHIOPRINE; CALCINEURIN; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SIROLIMUS; SKIN NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649455943     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.07.107     Document Type: Article

References (20)

1. J. Adami, H. Gabel, and B. Lindelof Cancer risk following organ transplantation: a nationwide cohort study in Sweden Br J Cancer 89 2003 1221
2. V. Ozduran, M.H. Yamani, and H.H. Chuang Survival beyond 10 years following heart transplantation: the Cleveland Clinic Foundation experience Transplant Proc 37 2005 4509
3. A. Koch, V. Daniel, and T.J. Dengler Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat) J Heart Lung Transplant 24 2005 708
4. M. Billingham, and J.A. Kobashigawa The revised ISHLT heart biopsy grading scale J Heart Lung Transplant 24 2005 1709
5. M.E. Billingham, N.R. Cary, and M.E. Hammond A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group The International Society for Heart Transplantation J Heart Transplant 9 1990 587
6. W.H. Cole The increase in immunosuppression and its role in the development of malignant lesions J Surg Oncol 30 1985 139
7. G. Opelz, and B. Dohler Lymphomas after solid organ transplantation: a collaborative transplant study report Am J Transplant 4 2004 222
8. M.G. Crespo-Leiro, M.J. Paniagua-Martin, and J. Muniz Long-term results of heart transplant in recipients older and younger than 65 years: a comparative study of mortality, rejections, and neoplasia in a cohort of 445 patients Transplant Proc 37 2005 4031
9. O. Landgren, E.S. Gilbert, and J.D. Rizzo Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation Blood 113 2009 4992
10. J.W. van Esser, B. van der Holt, and E. Meijer Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-celldepleted SCT Blood 98 2001 972
11. H.J. Wagner, C.M. Rooney, and H.E. Heslop Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation Biol Blood Marrow Transplant 8 2002 1
12. D.O. Taylor, L.B. Edwards, and M.M. Boucek Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report - 2006 J Heart Lung Transplant 25 2006 869
13. J.O. O'Neill, L.B. Edwards, and D.O. Taylor Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation J Heart Lung Transplant 25 2006 1186
14. V.J. Hemmens, and D.E. Moore Photochemical sensitization by azathioprine and its metabolitesII Azathioprine and nitroimidazole metabolites Photochem Photobiol 43 1986 257
15. A.H. Wilkinson, J.L. Smith, and L.G. Hunsicker Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone Transplantation 47 1989 293
16. E.K. Geissler The impact of mTOR inhibitors on the development of malignancy Transplant Proc 40 2008 S32
17. E.K. Geissler Fighting malignancy in organ transplant recipients Transplant Proc 41 2009 S9
18. A.O. Doesch, M. Konstandin, and S. Celik Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients Transpl Int 21 2008 963
19. M.L. Mihalov, P. Gattuso, and K. Abraham Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center Clin Transplant 10 1996 248
20. M.T. Olivari, R.A. Diekmann, and S.H. Kubo Low incidence of neoplasia in heart and heart-lung transplant recipients receiving triple-drug immunosuppression J Heart Transplant 9 1990 618